<p>We announced an agreement that Vertex Pharmaceuticals will acquire Crinetics Pharmaceuticals, further advancing our programs and supporting our patients</p>

Our Research

Phase 1 | General Research

CRN04894: Phase 1 Multiple Ascending Dose (MAD) Preliminary Results

Published: 2022
Authors: Company Presentation
Back to Publications

Related Publications

2024

Discovery of CRN04894: A Novel Potent Selective MC2R Antagonist

VIEW FULL PAPER
2025

Need to Pause Hydrocortisone? Physiologic Replacement Does Not Affect AM Serum Cortisol, Bedtime Salivary Cortisol or UFC in Cushing Syndrome Patients on Block and Replace Treatment

VIEW FULL PAPER
2022

CRN04894: First In Human Single Ascending Dose Preliminary Results

VIEW FULL PAPER